USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy

Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibitin...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications Vol. 13; no. 1; pp. 1700 - 17
Main Authors:	Xiong, Wenjun, Gao, Xueliang, Zhang, Tiantian, Jiang, Baishan, Hu, Ming-Ming, Bu, Xia, Gao, Yang, Zhang, Lin-Zhou, Xiao, Bo-Lin, He, Chuan, Sun, Yishuang, Li, Haiou, Shi, Jie, Xiao, Xiangling, Xiang, Bolin, Xie, Conghua, Chen, Gang, Zhang, Haojian, Wei, Wenyi, Freeman, Gordon J., Shu, Hong-Bing, Wang, Haizhen, Zhang, Jinfang
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 31.03.2022 Nature Publishing Group Nature Portfolio
Subjects:	13/31 38/88 45/90 45/91 631/337/458/582 631/67/327 64/60 Animal models Animals Anticancer properties CD8 antigen CD8-Positive T-Lymphocytes Cell Line, Tumor Endopeptidases - genetics Endosomal Sorting Complexes Required for Transport - genetics Humanities and Social Sciences Humans Immune response Immune system Immunotherapy Inflammation Inhibitors Innate immunity L1 protein Lymphocytes Lymphocytes T Major histocompatibility complex Mice multidisciplinary Neoplasms - drug therapy Neoplasms - genetics NF-κB protein PD-1 protein PD-L1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins Regulatory mechanisms (biology) Science Science (multidisciplinary) Signaling TRAF6 protein Tumor Microenvironment Tumors Ubiquitin Thiolesterase - antagonists & inhibitors Ubiquitin Thiolesterase - genetics Ubiquitination
ISSN:	2041-1723, 2041-1723
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8 + T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy. The regulatory mechanisms of PD-L1 posttranslational modifications are not completely understood. Here the authors show that USP8 negatively regulates PD-L1 protein abundance by removing the K63-linked ubiquitination of PD-L1; while USP8 inhibition increases MHC-I expression and triggers anti-tumour immune responses through activating NF-κB signalling.
AbstractList	Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8 + T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy. Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15-25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8 T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy. Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8+ T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy.The regulatory mechanisms of PD-L1 posttranslational modifications are not completely understood. Here the authors show that USP8 negatively regulates PD-L1 protein abundance by removing the K63-linked ubiquitination of PD-L1; while USP8 inhibition increases MHC-I expression and triggers anti-tumour immune responses through activating NF-κB signalling. Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8 + T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy. The regulatory mechanisms of PD-L1 posttranslational modifications are not completely understood. Here the authors show that USP8 negatively regulates PD-L1 protein abundance by removing the K63-linked ubiquitination of PD-L1; while USP8 inhibition increases MHC-I expression and triggers anti-tumour immune responses through activating NF-κB signalling. Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15-25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8+ T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy.Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15-25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8+ T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy. The regulatory mechanisms of PD-L1 posttranslational modifications are not completely understood. Here the authors show that USP8 negatively regulates PD-L1 protein abundance by removing the K63-linked ubiquitination of PD-L1; while USP8 inhibition increases MHC-I expression and triggers anti-tumour immune responses through activating NF-κB signalling.
ArticleNumber	1700
Author	Zhang, Tiantian Gao, Xueliang Shu, Hong-Bing Gao, Yang He, Chuan Sun, Yishuang Wang, Haizhen Freeman, Gordon J. Hu, Ming-Ming Shi, Jie Xie, Conghua Xiao, Bo-Lin Xiang, Bolin Xiao, Xiangling Zhang, Haojian Xiong, Wenjun Chen, Gang Wei, Wenyi Zhang, Jinfang Bu, Xia Li, Haiou Zhang, Lin-Zhou Jiang, Baishan
Author_xml	– sequence: 1 givenname: Wenjun surname: Xiong fullname: Xiong, Wenjun organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 2 givenname: Xueliang surname: Gao fullname: Gao, Xueliang organization: Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina – sequence: 3 givenname: Tiantian surname: Zhang fullname: Zhang, Tiantian organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 4 givenname: Baishan orcidid: 0000-0001-6796-9500 surname: Jiang fullname: Jiang, Baishan organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, Center for Protein Degradation, Dana-Farber Cancer Institute, Harvard Medical School – sequence: 5 givenname: Ming-Ming surname: Hu fullname: Hu, Ming-Ming organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, Department of Infectious Diseases, Zhongnan Hospital of Wuhan University – sequence: 6 givenname: Xia surname: Bu fullname: Bu, Xia organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School – sequence: 7 givenname: Yang surname: Gao fullname: Gao, Yang organization: Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School – sequence: 8 givenname: Lin-Zhou surname: Zhang fullname: Zhang, Lin-Zhou organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education and Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 9 givenname: Bo-Lin surname: Xiao fullname: Xiao, Bo-Lin organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education and Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 10 givenname: Chuan surname: He fullname: He, Chuan organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 11 givenname: Yishuang surname: Sun fullname: Sun, Yishuang organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 12 givenname: Haiou surname: Li fullname: Li, Haiou organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, Department of Dermatology, Zhongnan Hospital of Wuhan University – sequence: 13 givenname: Jie surname: Shi fullname: Shi, Jie organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 14 givenname: Xiangling surname: Xiao fullname: Xiao, Xiangling organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 15 givenname: Bolin surname: Xiang fullname: Xiang, Bolin organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 16 givenname: Conghua orcidid: 0000-0001-6623-9864 surname: Xie fullname: Xie, Conghua organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University – sequence: 17 givenname: Gang orcidid: 0000-0003-3332-3511 surname: Chen fullname: Chen, Gang organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education and Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University – sequence: 18 givenname: Haojian surname: Zhang fullname: Zhang, Haojian organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University – sequence: 19 givenname: Wenyi orcidid: 0000-0003-0512-3811 surname: Wei fullname: Wei, Wenyi organization: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School – sequence: 20 givenname: Gordon J. orcidid: 0000-0002-7210-5616 surname: Freeman fullname: Freeman, Gordon J. organization: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School – sequence: 21 givenname: Hong-Bing orcidid: 0000-0001-9102-3272 surname: Shu fullname: Shu, Hong-Bing organization: Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University, Department of Infectious Diseases, Zhongnan Hospital of Wuhan University – sequence: 22 givenname: Haizhen orcidid: 0000-0003-3477-8673 surname: Wang fullname: Wang, Haizhen email: wangha@musc.edu organization: Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina – sequence: 23 givenname: Jinfang orcidid: 0000-0001-8487-6007 surname: Zhang fullname: Zhang, Jinfang email: jinfang_zhang@whu.edu.cn organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, School of Medicine, Wuhan University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35361799$$D View this record in MEDLINE/PubMed
BookMark	eNp9Ustu1TAUjFARLaU_wAJFYsMmxW_HGyRU8ahUCSToFutcx7nxVWIH26nUv8e3KX0t6o2P7JnxHJ95XR344G1VvcXoFCPafkwMMyEbREhDFEO4ES-qI4IYbrAk9OBBfVidpLRDZVGFW8ZeVYeUU4GlUkfVn8tfP9va-cFtXHbB19GmAWabavDluB9hsl2dlynEenImBuuvXAx-sj7XeYBczyGX2kEunDzY2k3T4kOpIszXb6qXPYzJntzux9Xl1y-_z743Fz--nZ99vmgMZyg3gGlnWkEo48bIjrCup1wwxjplQTKj2IZx1EvcIWuRaEVHNkwqwwEbZFtJj6vzVbcLsNNzdBPEax3A6ZuDELcaYnZmtNpKoZDESiHeMhAAiBYRwhkpumBp0fq0as3LpjRvSncRxkeij2-8G_Q2XOlWScwILwIfbgVi-LvYlPXkkrHjCN6GJWkiyuSIRGLv-_0T6C4s0Zev2qO4FLzFe0fvHjq6s_J_jAVAVkAZUErR9ncQjPQ-LnqNiy5x0Tdx0aKQ2ick4zLsQ1C6cuPzVLpSU3nHb228t_0M6x_KZNPa
CitedBy_id	crossref_primary_10_1186_s40164_022_00297_8 crossref_primary_10_1016_j_jconrel_2024_08_008 crossref_primary_10_1073_pnas_2315541121 crossref_primary_10_1186_s12964_024_01805_5 crossref_primary_10_1016_j_drudis_2025_104356 crossref_primary_10_1021_acsmaterialslett_5c00097 crossref_primary_10_1016_j_ymthe_2025_01_047 crossref_primary_10_7717_peerj_19550 crossref_primary_10_1016_j_ejmech_2024_116275 crossref_primary_10_7554_eLife_96353_4 crossref_primary_10_1016_j_gene_2024_148175 crossref_primary_10_1155_2023_8483325 crossref_primary_10_1002_mco2_343 crossref_primary_10_1038_s41392_025_02171_5 crossref_primary_10_3389_fimmu_2025_1596451 crossref_primary_10_3389_fimmu_2023_1123244 crossref_primary_10_1083_jcb_202306013 crossref_primary_10_1016_j_trecan_2025_02_004 crossref_primary_10_1038_s41392_024_01757_9 crossref_primary_10_1186_s12935_024_03370_w crossref_primary_10_3389_fimmu_2023_1228200 crossref_primary_10_1016_j_biopha_2022_114150 crossref_primary_10_1016_j_canlet_2024_216836 crossref_primary_10_1016_j_jconrel_2024_11_076 crossref_primary_10_1186_s12957_025_03667_8 crossref_primary_10_3390_ijms25052939 crossref_primary_10_1016_j_arcmed_2023_102899 crossref_primary_10_1186_s12967_024_05572_2 crossref_primary_10_1038_s42003_025_08409_w crossref_primary_10_1128_spectrum_00326_23 crossref_primary_10_1016_j_jconrel_2024_08_013 crossref_primary_10_1016_j_jad_2025_119647 crossref_primary_10_1186_s12943_024_02005_y crossref_primary_10_1080_15548627_2024_2395134 crossref_primary_10_3389_fimmu_2025_1518555 crossref_primary_10_1016_j_biopha_2022_113618 crossref_primary_10_1186_s13062_025_00638_7 crossref_primary_10_1016_j_semcancer_2025_02_004 crossref_primary_10_1038_s41467_024_50138_x crossref_primary_10_3389_fimmu_2023_1226057 crossref_primary_10_1136_ard_2023_224503 crossref_primary_10_1186_s12943_024_02046_3 crossref_primary_10_1016_j_str_2025_05_005 crossref_primary_10_1186_s40001_023_01388_w crossref_primary_10_1111_1759_7714_15489 crossref_primary_10_1002_advs_202303807 crossref_primary_10_1016_j_chembiol_2023_09_001 crossref_primary_10_3389_fimmu_2024_1392546 crossref_primary_10_1186_s12943_025_02397_5 crossref_primary_10_1038_s41419_024_07324_y crossref_primary_10_1002_advs_202406962 crossref_primary_10_1172_JCI160456 crossref_primary_10_1002_adma_202207330 crossref_primary_10_1016_j_canlet_2024_216861 crossref_primary_10_1038_s41419_024_07219_y crossref_primary_10_1186_s13148_024_01698_8 crossref_primary_10_3389_fonc_2024_1437953 crossref_primary_10_1002_advs_202303175 crossref_primary_10_1038_s41467_025_59621_5 crossref_primary_10_1186_s12964_024_01633_7 crossref_primary_10_1158_2326_6066_CIR_24_1179 crossref_primary_10_3390_cancers16203487 crossref_primary_10_3389_fimmu_2025_1616321 crossref_primary_10_3389_fimmu_2024_1340307 crossref_primary_10_1016_j_bbcan_2023_188873 crossref_primary_10_3390_biom13121724 crossref_primary_10_1016_j_phrs_2025_107853 crossref_primary_10_1038_s41467_023_38605_3 crossref_primary_10_1016_j_intimp_2023_110970 crossref_primary_10_1186_s40164_023_00394_2 crossref_primary_10_1016_j_tranon_2023_101789 crossref_primary_10_1007_s00262_024_03731_4 crossref_primary_10_1016_j_intimp_2025_115024 crossref_primary_10_7554_eLife_96353 crossref_primary_10_1016_j_heliyon_2024_e28600 crossref_primary_10_1016_j_intimp_2024_112098 crossref_primary_10_3892_ol_2025_15049 crossref_primary_10_1002_advs_202405083 crossref_primary_10_1016_j_canlet_2023_216440 crossref_primary_10_1016_j_ygeno_2024_110907 crossref_primary_10_1186_s40164_024_00552_0 crossref_primary_10_1002_advs_202302953 crossref_primary_10_1186_s40164_025_00627_6 crossref_primary_10_1038_s41423_024_01193_3 crossref_primary_10_1007_s10495_025_02095_z crossref_primary_10_1042_BST20230454
Cites_doi	10.1038/cr.2015.20 10.1128/MCB.01566-06 10.1016/j.cell.2017.01.017 10.1074/jbc.M609503200 10.1016/j.ccell.2016.10.010 10.1038/ni.3230 10.1371/journal.pgen.1007456 10.1038/s41467-020-19973-6 10.1038/s41580-019-0099-1 10.1038/s41467-019-09430-4 10.1016/j.immuni.2018.03.014 10.1111/imr.12302 10.1016/j.ccell.2020.11.009 10.1038/ncomms5763 10.1038/nrd.2017.152 10.1038/nature00888 10.1158/1940-6207.CAPR-08-0147 10.1016/S0092-8674(00)00126-4 10.1038/nature23669 10.1016/j.immuni.2019.12.011 10.1038/nrm3099 10.1016/j.bmcl.2005.09.035 10.1038/35085597 10.1038/onc.2016.215 10.1038/s41418-019-0419-1 10.1038/s41591-018-0136-1 10.1126/science.aar4060 10.1111/j.1600-065X.2012.01108.x 10.1158/1078-0432.CCR-12-3696 10.1074/jbc.M110.129411 10.1038/s41577-019-0218-4 10.1016/j.cellsig.2008.05.013 10.1038/nature25015 10.15252/embj.201489729 10.1126/science.aau0159 10.1126/scitranslmed.aat7807 10.1038/nature23643 10.1038/s43018-020-00161-w 10.1016/j.ccell.2018.03.005 10.1038/nature22344 10.1042/BST20190527 10.1038/s41556-020-0562-4 10.1016/j.cell.2012.02.065 10.1038/ng.3166 10.1146/annurev-biochem-060310-170328 10.1126/science.aao4572 10.1038/ncomms12632 10.1074/jbc.M109.016287 10.1007/978-1-4939-9167-9_8 10.1016/j.tibs.2018.09.004 10.1158/2159-8290.CD-12-0095 10.1158/1078-0432.CCR-09-1225 10.1038/nrm2468 10.1016/j.ccell.2016.02.004 10.1242/jcs.183954
ContentType	Journal Article
Copyright	The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA
DOI	10.1038/s41467-022-29401-6
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE Publicly Available Content Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2041-1723
EndPage	17
ExternalDocumentID	oai_doaj_org_article_e769071990584a6aa031c02542686ae3 PMC8971425 35361799 10_1038_s41467_022_29401_6
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 31970732 funderid: https://doi.org/10.13039/501100001809 – fundername: NCI NIH HHS grantid: P50 CA101942 – fundername: NCI NIH HHS grantid: R37 CA251165 – fundername: ; grantid: 31970732
GroupedDBID	--- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LK8 M1P M48 M7P M~E NAO O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX AFFHD CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c540t-a13dc862345cc7d24df356444d9ea74c94b450f71d0ee0686d2b479c5a1c0e873
IEDL.DBID	DOA
ISICitedReferencesCount	102
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000777008300020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2041-1723
IngestDate	Tue Oct 14 18:42:56 EDT 2025 Tue Nov 04 01:56:45 EST 2025 Fri Sep 05 12:58:33 EDT 2025 Tue Oct 07 06:45:03 EDT 2025 Wed Feb 19 02:26:48 EST 2025 Sat Nov 29 06:29:46 EST 2025 Tue Nov 18 21:04:29 EST 2025 Fri Feb 21 02:38:53 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c540t-a13dc862345cc7d24df356444d9ea74c94b450f71d0ee0686d2b479c5a1c0e873
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-3332-3511 0000-0002-7210-5616 0000-0001-9102-3272 0000-0001-6623-9864 0000-0003-3477-8673 0000-0001-8487-6007 0000-0001-6796-9500 0000-0003-0512-3811
OpenAccessLink	https://doaj.org/article/e769071990584a6aa031c02542686ae3
PMID	35361799
PQID	2645765813
PQPubID	546298
PageCount	17
ParticipantIDs	doaj_primary_oai_doaj_org_article_e769071990584a6aa031c02542686ae3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8971425 proquest_miscellaneous_2646727067 proquest_journals_2645765813 pubmed_primary_35361799 crossref_primary_10_1038_s41467_022_29401_6 crossref_citationtrail_10_1038_s41467_022_29401_6 springer_journals_10_1038_s41467_022_29401_6
PublicationCentury	2000
PublicationDate	2022-03-31
PublicationDateYYYYMMDD	2022-03-31
PublicationDate_xml	– month: 03 year: 2022 text: 2022-03-31 day: 31
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Nature communications
PublicationTitleAbbrev	Nat Commun
PublicationTitleAlternate	Nat Commun
PublicationYear	2022
Publisher	Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio
References	Tang (CR43) 2016; 29 Chowell (CR42) 2018; 359 Jeong (CR27) 2017; 36 Akutsu, Dikic, Bremm (CR14) 2016; 129 Waelchli (CR48) 2006; 16 Gu (CR34) 2019; 10 Deng (CR39) 2000; 103 Hegde, Chen (CR5) 2020; 52 Ma (CR29) 2015; 25 Clague, Urbe, Komander (CR22) 2019; 20 Byun (CR25) 2013; 19 Moon (CR47) 2021; 2 Funakoshi-Tago (CR38) 2008; 20 Ribas, Wolchok (CR1) 2018; 359 Tan, Lei (CR55) 2019; 1960 Zhang (CR17) 2018; 553 Crespo-Yanez (CR24) 2018; 14 Ravid, Hochstrasser (CR15) 2008; 9 Komander, Rape (CR12) 2012; 81 Ye (CR40) 2002; 418 Zhang, Dang, Ren, Wei (CR7) 2018; 43 Sun, Mezzadra, Schumacher (CR8) 2018; 48 Reincke (CR28) 2015; 47 Lee (CR51) 2019; 364 Durcan (CR33) 2014; 33 Czerninski, Amornphimoltham, Patel, Molinolo, Gutkind (CR53) 2009; 2 Zhang (CR54) 2020; 11 Harrigan, Jacq, Martin, Jackson (CR21) 2018; 17 Cerami (CR52) 2012; 2 Zappasodi, Merghoub, Wolchok (CR2) 2018; 33 Berlin, Schwartz, Nash (CR31) 2010; 285 Mezzadra (CR20) 2017; 549 Galluzzi, Chan, Kroemer, Wolchok, Lopez-Soto (CR6) 2018; 10 Walsh, Lee, Choi (CR49) 2015; 266 Wang (CR45) 2001; 412 Chan (CR41) 2012; 149 Berlin, Higginbotham, Dise, Sierra, Nash (CR36) 2010; 285 Jiang (CR44) 2018; 24 Lim (CR37) 2016; 30 Burr (CR19) 2017; 549 Dufner, Knobeloch (CR23) 2019; 47 Lamothe (CR46) 2007; 282 Kalbasi, Ribas (CR4) 2020; 20 Li (CR18) 2016; 7 Niendorf (CR32) 2007; 27 Chen (CR16) 2012; 246 Grabbe, Husnjak, Dikic (CR13) 2011; 12 Ritorto (CR35) 2014; 5 Wang (CR50) 2017; 545 Dufner (CR30) 2015; 16 Gao (CR9) 2020; 22 Martinez-Forero, Rouzaut, Palazon, Dubrot, Melero (CR11) 2009; 15 Sharma, Hu-Lieskovan, Wargo, Ribas (CR3) 2017; 168 Petroni, Buque, Zitvogel, Kroemer, Galluzzi (CR10) 2020; 39 Shin (CR26) 2020; 27 C Grabbe (29401_CR13) 2011; 12 YS Tan (29401_CR55) 2019; 1960 M Reincke (29401_CR28) 2015; 47 CH Chan (29401_CR41) 2012; 149 M Akutsu (29401_CR14) 2016; 129 SO Lim (29401_CR37) 2016; 30 ZJ Chen (29401_CR16) 2012; 246 CW Li (29401_CR18) 2016; 7 X Crespo-Yanez (29401_CR24) 2018; 14 M Funakoshi-Tago (29401_CR38) 2008; 20 ZY Ma (29401_CR29) 2015; 25 Y Gao (29401_CR9) 2020; 22 H Gu (29401_CR34) 2019; 10 PS Hegde (29401_CR5) 2020; 52 H Ye (29401_CR40) 2002; 418 JA Harrigan (29401_CR21) 2018; 17 I Berlin (29401_CR36) 2010; 285 L Galluzzi (29401_CR6) 2018; 10 R Czerninski (29401_CR53) 2009; 2 M Jeong (29401_CR27) 2017; 36 A Kalbasi (29401_CR4) 2020; 20 S Niendorf (29401_CR32) 2007; 27 R Waelchli (29401_CR48) 2006; 16 CS Moon (29401_CR47) 2021; 2 ML Burr (29401_CR19) 2017; 549 L Deng (29401_CR39) 2000; 103 P Sharma (29401_CR3) 2017; 168 R Zappasodi (29401_CR2) 2018; 33 J Zhang (29401_CR7) 2018; 43 YR Lee (29401_CR51) 2019; 364 C Wang (29401_CR45) 2001; 412 R Mezzadra (29401_CR20) 2017; 549 S Shin (29401_CR26) 2020; 27 C Sun (29401_CR8) 2018; 48 H Tang (29401_CR43) 2016; 29 A Ribas (29401_CR1) 2018; 359 I Martinez-Forero (29401_CR11) 2009; 15 D Komander (29401_CR12) 2012; 81 E Cerami (29401_CR52) 2012; 2 TM Durcan (29401_CR33) 2014; 33 D Chowell (29401_CR42) 2018; 359 P Jiang (29401_CR44) 2018; 24 MC Walsh (29401_CR49) 2015; 266 B Wang (29401_CR50) 2017; 545 I Berlin (29401_CR31) 2010; 285 G Petroni (29401_CR10) 2020; 39 A Dufner (29401_CR23) 2019; 47 B Lamothe (29401_CR46) 2007; 282 MJ Clague (29401_CR22) 2019; 20 J Zhang (29401_CR17) 2018; 553 MS Ritorto (29401_CR35) 2014; 5 M Zhang (29401_CR54) 2020; 11 T Ravid (29401_CR15) 2008; 9 A Dufner (29401_CR30) 2015; 16 S Byun (29401_CR25) 2013; 19
References_xml	– volume: 25 start-page: 306 year: 2015 end-page: 317 ident: CR29 article-title: Recurrent gain-of-function USP8 mutations in Cushing’s disease publication-title: Cell Res. doi: 10.1038/cr.2015.20 – volume: 27 start-page: 5029 year: 2007 end-page: 5039 ident: CR32 article-title: Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.01566-06 – volume: 168 start-page: 707 year: 2017 end-page: 723 ident: CR3 article-title: Primary, adaptive, and acquired resistance to cancer immunotherapy publication-title: Cell doi: 10.1016/j.cell.2017.01.017 – volume: 282 start-page: 4102 year: 2007 end-page: 4112 ident: CR46 article-title: Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation publication-title: J. Biol. Chem. doi: 10.1074/jbc.M609503200 – volume: 30 start-page: 925 year: 2016 end-page: 939 ident: CR37 article-title: Deubiquitination and stabilization of PD-L1 by CSN5 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.10.010 – volume: 16 start-page: 950 year: 2015 end-page: 960 ident: CR30 article-title: The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells publication-title: Nat. Immunol. doi: 10.1038/ni.3230 – volume: 14 start-page: e1007456 year: 2018 ident: CR24 article-title: CHMP1B is a target of USP8/UBPY regulated by ubiquitin during endocytosis publication-title: PLoS Genet. doi: 10.1371/journal.pgen.1007456 – volume: 11 year: 2020 ident: CR54 article-title: CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer publication-title: Nat. Commun. doi: 10.1038/s41467-020-19973-6 – volume: 20 start-page: 338 year: 2019 end-page: 352 ident: CR22 article-title: Breaking the chains: deubiquitylating enzyme specificity begets function publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-019-0099-1 – volume: 10 year: 2019 ident: CR34 article-title: USP8 maintains embryonic stem cell stemness via deubiquitination of EPG5 publication-title: Nat. Commun. doi: 10.1038/s41467-019-09430-4 – volume: 48 start-page: 434 year: 2018 end-page: 452 ident: CR8 article-title: Regulation and function of the PD-L1 checkpoint publication-title: Immunity doi: 10.1016/j.immuni.2018.03.014 – volume: 266 start-page: 72 year: 2015 end-page: 92 ident: CR49 article-title: Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system publication-title: Immunol. Rev. doi: 10.1111/imr.12302 – volume: 39 start-page: 310 year: 2020 end-page: 345 ident: CR10 article-title: Immunomodulation by targeted anticancer agents publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.11.009 – volume: 5 year: 2014 ident: CR35 article-title: Screening of DUB activity and specificity by MALDI-TOF mass spectrometry publication-title: Nat. Commun. doi: 10.1038/ncomms5763 – volume: 17 start-page: 57 year: 2018 end-page: 78 ident: CR21 article-title: Deubiquitylating enzymes and drug discovery: emerging opportunities publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2017.152 – volume: 418 start-page: 443 year: 2002 end-page: 447 ident: CR40 article-title: Distinct molecular mechanism for initiating TRAF6 signalling publication-title: Nature doi: 10.1038/nature00888 – volume: 2 start-page: 27 year: 2009 end-page: 36 ident: CR53 article-title: Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model publication-title: Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-08-0147 – volume: 103 start-page: 351 year: 2000 end-page: 361 ident: CR39 article-title: Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain publication-title: Cell doi: 10.1016/S0092-8674(00)00126-4 – volume: 549 start-page: 106 year: 2017 end-page: 110 ident: CR20 article-title: Identification of CMTM6 and CMTM4 as PD-L1 protein regulators publication-title: Nature doi: 10.1038/nature23669 – volume: 52 start-page: 17 year: 2020 end-page: 35 ident: CR5 article-title: Top 10 challenges in cancer immunotherapy publication-title: Immunity doi: 10.1016/j.immuni.2019.12.011 – volume: 12 start-page: 295 year: 2011 end-page: 307 ident: CR13 article-title: The spatial and temporal organization of ubiquitin networks publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm3099 – volume: 16 start-page: 108 year: 2006 end-page: 112 ident: CR48 article-title: Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2005.09.035 – volume: 412 start-page: 346 year: 2001 end-page: 351 ident: CR45 article-title: TAK1 is a ubiquitin-dependent kinase of MKK and IKK publication-title: Nature doi: 10.1038/35085597 – volume: 36 start-page: 458 year: 2017 end-page: 470 ident: CR27 article-title: USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability publication-title: Oncogene doi: 10.1038/onc.2016.215 – volume: 27 start-page: 1341 year: 2020 end-page: 1354 ident: CR26 article-title: Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer publication-title: Cell Death Differ. doi: 10.1038/s41418-019-0419-1 – volume: 24 start-page: 1550 year: 2018 end-page: 1558 ident: CR44 article-title: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response publication-title: Nat. Med. doi: 10.1038/s41591-018-0136-1 – volume: 359 start-page: 1350 year: 2018 end-page: 1355 ident: CR1 article-title: Cancer immunotherapy using checkpoint blockade publication-title: Science doi: 10.1126/science.aar4060 – volume: 246 start-page: 95 year: 2012 end-page: 106 ident: CR16 article-title: Ubiquitination in signaling to and activation of IKK publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2012.01108.x – volume: 19 start-page: 3894 year: 2013 end-page: 3904 ident: CR25 article-title: USP8 is a novel target for overcoming gefitinib resistance in lung cancer publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-12-3696 – volume: 285 start-page: 37895 year: 2010 end-page: 37908 ident: CR36 article-title: The deubiquitinating enzyme USP8 promotes trafficking and degradation of the chemokine receptor 4 at the sorting endosome publication-title: J. Biol. Chem. doi: 10.1074/jbc.M110.129411 – volume: 20 start-page: 25 year: 2020 end-page: 39 ident: CR4 article-title: Tumour-intrinsic resistance to immune checkpoint blockade publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0218-4 – volume: 20 start-page: 1679 year: 2008 end-page: 1686 ident: CR38 article-title: TRAF6 is a critical signal transducer in IL-33 signaling pathway publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2008.05.013 – volume: 553 start-page: 91 year: 2018 end-page: 95 ident: CR17 article-title: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance publication-title: Nature doi: 10.1038/nature25015 – volume: 33 start-page: 2473 year: 2014 end-page: 2491 ident: CR33 article-title: USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin publication-title: EMBO J. doi: 10.15252/embj.201489729 – volume: 364 start-page: eaau0159 year: 2019 ident: CR51 article-title: Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway publication-title: Science doi: 10.1126/science.aau0159 – volume: 10 start-page: eaat7807 year: 2018 ident: CR6 article-title: The hallmarks of successful anticancer immunotherapy publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aat7807 – volume: 549 start-page: 101 year: 2017 end-page: 105 ident: CR19 article-title: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity publication-title: Nature doi: 10.1038/nature23643 – volume: 2 start-page: 98 year: 2021 end-page: 113 ident: CR47 article-title: FYN-TRAF3IP2 induces NF-kappaB signaling-driven peripheral T cell lymphoma publication-title: Nat. Cancer doi: 10.1038/s43018-020-00161-w – volume: 33 start-page: 581 year: 2018 end-page: 598 ident: CR2 article-title: Emerging concepts for immune checkpoint blockade-based combination therapies publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.03.005 – volume: 545 start-page: 365 year: 2017 end-page: 369 ident: CR50 article-title: TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling publication-title: Nature doi: 10.1038/nature22344 – volume: 47 start-page: 1867 year: 2019 end-page: 1879 ident: CR23 article-title: Ubiquitin-specific protease 8 (USP8/UBPy): a prototypic multidomain deubiquitinating enzyme with pleiotropic functions publication-title: Biochemical Soc. Trans. doi: 10.1042/BST20190527 – volume: 22 start-page: 1064 year: 2020 end-page: 1075 ident: CR9 article-title: Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy publication-title: Nat. Cell Biol. doi: 10.1038/s41556-020-0562-4 – volume: 149 start-page: 1098 year: 2012 end-page: 1111 ident: CR41 article-title: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis publication-title: Cell doi: 10.1016/j.cell.2012.02.065 – volume: 47 start-page: 31 year: 2015 end-page: 38 ident: CR28 article-title: Mutations in the deubiquitinase gene USP8 cause Cushing’s disease publication-title: Nat. Genet. doi: 10.1038/ng.3166 – volume: 129 start-page: 875 year: 2016 end-page: 880 ident: CR14 article-title: Ubiquitin chain diversity at a glance publication-title: J. Cell Sci. – volume: 81 start-page: 203 year: 2012 end-page: 229 ident: CR12 article-title: The ubiquitin code publication-title: Annu Rev. Biochem. doi: 10.1146/annurev-biochem-060310-170328 – volume: 359 start-page: 582 year: 2018 end-page: 587 ident: CR42 article-title: Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy publication-title: Science doi: 10.1126/science.aao4572 – volume: 7 year: 2016 ident: CR18 article-title: Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity publication-title: Nat. Commun. doi: 10.1038/ncomms12632 – volume: 285 start-page: 34909 year: 2010 end-page: 34921 ident: CR31 article-title: Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8.STAM complex publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.016287 – volume: 1960 start-page: 93 year: 2019 end-page: 99 ident: CR55 article-title: Isolation of tumor-infiltrating lymphocytes by ficoll-paque density gradient centrifugation publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-9167-9_8 – volume: 43 start-page: 1014 year: 2018 end-page: 1032 ident: CR7 article-title: Biochemical aspects of PD-L1 regulation in cancer immunotherapy publication-title: Trends Biochemical Sci. doi: 10.1016/j.tibs.2018.09.004 – volume: 2 start-page: 401 year: 2012 end-page: 404 ident: CR52 article-title: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0095 – volume: 15 start-page: 6751 year: 2009 end-page: 6757 ident: CR11 article-title: Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-1225 – volume: 9 start-page: 679 year: 2008 end-page: 690 ident: CR15 article-title: Diversity of degradation signals in the ubiquitin-proteasome system publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm2468 – volume: 29 start-page: 285 year: 2016 end-page: 296 ident: CR43 article-title: Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade publication-title: Cancer cell doi: 10.1016/j.ccell.2016.02.004 – volume: 36 start-page: 458 year: 2017 ident: 29401_CR27 publication-title: Oncogene doi: 10.1038/onc.2016.215 – volume: 418 start-page: 443 year: 2002 ident: 29401_CR40 publication-title: Nature doi: 10.1038/nature00888 – volume: 16 start-page: 950 year: 2015 ident: 29401_CR30 publication-title: Nat. Immunol. doi: 10.1038/ni.3230 – volume: 20 start-page: 25 year: 2020 ident: 29401_CR4 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0218-4 – volume: 19 start-page: 3894 year: 2013 ident: 29401_CR25 publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-12-3696 – volume: 39 start-page: 310 year: 2020 ident: 29401_CR10 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.11.009 – volume: 27 start-page: 5029 year: 2007 ident: 29401_CR32 publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.01566-06 – volume: 11 year: 2020 ident: 29401_CR54 publication-title: Nat. Commun. doi: 10.1038/s41467-020-19973-6 – volume: 20 start-page: 338 year: 2019 ident: 29401_CR22 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/s41580-019-0099-1 – volume: 149 start-page: 1098 year: 2012 ident: 29401_CR41 publication-title: Cell doi: 10.1016/j.cell.2012.02.065 – volume: 81 start-page: 203 year: 2012 ident: 29401_CR12 publication-title: Annu Rev. Biochem. doi: 10.1146/annurev-biochem-060310-170328 – volume: 285 start-page: 37895 year: 2010 ident: 29401_CR36 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M110.129411 – volume: 545 start-page: 365 year: 2017 ident: 29401_CR50 publication-title: Nature doi: 10.1038/nature22344 – volume: 33 start-page: 2473 year: 2014 ident: 29401_CR33 publication-title: EMBO J. doi: 10.15252/embj.201489729 – volume: 246 start-page: 95 year: 2012 ident: 29401_CR16 publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2012.01108.x – volume: 20 start-page: 1679 year: 2008 ident: 29401_CR38 publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2008.05.013 – volume: 47 start-page: 31 year: 2015 ident: 29401_CR28 publication-title: Nat. Genet. doi: 10.1038/ng.3166 – volume: 16 start-page: 108 year: 2006 ident: 29401_CR48 publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2005.09.035 – volume: 5 year: 2014 ident: 29401_CR35 publication-title: Nat. Commun. doi: 10.1038/ncomms5763 – volume: 364 start-page: eaau0159 year: 2019 ident: 29401_CR51 publication-title: Science doi: 10.1126/science.aau0159 – volume: 33 start-page: 581 year: 2018 ident: 29401_CR2 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.03.005 – volume: 129 start-page: 875 year: 2016 ident: 29401_CR14 publication-title: J. Cell Sci. doi: 10.1242/jcs.183954 – volume: 7 year: 2016 ident: 29401_CR18 publication-title: Nat. Commun. doi: 10.1038/ncomms12632 – volume: 285 start-page: 34909 year: 2010 ident: 29401_CR31 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.016287 – volume: 17 start-page: 57 year: 2018 ident: 29401_CR21 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2017.152 – volume: 29 start-page: 285 year: 2016 ident: 29401_CR43 publication-title: Cancer cell doi: 10.1016/j.ccell.2016.02.004 – volume: 2 start-page: 98 year: 2021 ident: 29401_CR47 publication-title: Nat. Cancer doi: 10.1038/s43018-020-00161-w – volume: 2 start-page: 27 year: 2009 ident: 29401_CR53 publication-title: Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-08-0147 – volume: 14 start-page: e1007456 year: 2018 ident: 29401_CR24 publication-title: PLoS Genet. doi: 10.1371/journal.pgen.1007456 – volume: 10 start-page: eaat7807 year: 2018 ident: 29401_CR6 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aat7807 – volume: 43 start-page: 1014 year: 2018 ident: 29401_CR7 publication-title: Trends Biochemical Sci. doi: 10.1016/j.tibs.2018.09.004 – volume: 30 start-page: 925 year: 2016 ident: 29401_CR37 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.10.010 – volume: 48 start-page: 434 year: 2018 ident: 29401_CR8 publication-title: Immunity doi: 10.1016/j.immuni.2018.03.014 – volume: 47 start-page: 1867 year: 2019 ident: 29401_CR23 publication-title: Biochemical Soc. Trans. doi: 10.1042/BST20190527 – volume: 24 start-page: 1550 year: 2018 ident: 29401_CR44 publication-title: Nat. Med. doi: 10.1038/s41591-018-0136-1 – volume: 103 start-page: 351 year: 2000 ident: 29401_CR39 publication-title: Cell doi: 10.1016/S0092-8674(00)00126-4 – volume: 12 start-page: 295 year: 2011 ident: 29401_CR13 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm3099 – volume: 22 start-page: 1064 year: 2020 ident: 29401_CR9 publication-title: Nat. Cell Biol. doi: 10.1038/s41556-020-0562-4 – volume: 266 start-page: 72 year: 2015 ident: 29401_CR49 publication-title: Immunol. Rev. doi: 10.1111/imr.12302 – volume: 2 start-page: 401 year: 2012 ident: 29401_CR52 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0095 – volume: 10 year: 2019 ident: 29401_CR34 publication-title: Nat. Commun. doi: 10.1038/s41467-019-09430-4 – volume: 9 start-page: 679 year: 2008 ident: 29401_CR15 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm2468 – volume: 412 start-page: 346 year: 2001 ident: 29401_CR45 publication-title: Nature doi: 10.1038/35085597 – volume: 168 start-page: 707 year: 2017 ident: 29401_CR3 publication-title: Cell doi: 10.1016/j.cell.2017.01.017 – volume: 15 start-page: 6751 year: 2009 ident: 29401_CR11 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-1225 – volume: 25 start-page: 306 year: 2015 ident: 29401_CR29 publication-title: Cell Res. doi: 10.1038/cr.2015.20 – volume: 1960 start-page: 93 year: 2019 ident: 29401_CR55 publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-9167-9_8 – volume: 549 start-page: 106 year: 2017 ident: 29401_CR20 publication-title: Nature doi: 10.1038/nature23669 – volume: 359 start-page: 1350 year: 2018 ident: 29401_CR1 publication-title: Science doi: 10.1126/science.aar4060 – volume: 282 start-page: 4102 year: 2007 ident: 29401_CR46 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M609503200 – volume: 52 start-page: 17 year: 2020 ident: 29401_CR5 publication-title: Immunity doi: 10.1016/j.immuni.2019.12.011 – volume: 359 start-page: 582 year: 2018 ident: 29401_CR42 publication-title: Science doi: 10.1126/science.aao4572 – volume: 549 start-page: 101 year: 2017 ident: 29401_CR19 publication-title: Nature doi: 10.1038/nature23643 – volume: 27 start-page: 1341 year: 2020 ident: 29401_CR26 publication-title: Cell Death Differ. doi: 10.1038/s41418-019-0419-1 – volume: 553 start-page: 91 year: 2018 ident: 29401_CR17 publication-title: Nature doi: 10.1038/nature25015
SSID	ssj0000391844
Score	2.6404593
Snippet	Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular... The regulatory mechanisms of PD-L1 posttranslational modifications are not completely understood. Here the authors show that USP8 negatively regulates PD-L1...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1700
SubjectTerms	13/31 38/88 45/90 45/91 631/337/458/582 631/67/327 64/60 Animal models Animals Anticancer properties CD8 antigen CD8-Positive T-Lymphocytes Cell Line, Tumor Endopeptidases - genetics Endosomal Sorting Complexes Required for Transport - genetics Humanities and Social Sciences Humans Immune response Immune system Immunotherapy Inflammation Inhibitors Innate immunity L1 protein Lymphocytes Lymphocytes T Major histocompatibility complex Mice multidisciplinary Neoplasms - drug therapy Neoplasms - genetics NF-κB protein PD-1 protein PD-L1 protein Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins Regulatory mechanisms (biology) Science Science (multidisciplinary) Signaling TRAF6 protein Tumor Microenvironment Tumors Ubiquitin Thiolesterase - antagonists & inhibitors Ubiquitin Thiolesterase - genetics Ubiquitination
SummonAdditionalLinks	– databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BAYkL70egoCBxg6hJ7MTOCQGi4oCqlaBST1iO7XQj0WRJskj998w43i3Loxeujleydx7-7Jn5BuAlej4jCy2SvG5cwg0TSV3IOmG2LAvWNIg4PInrJ3F0JE9OqkV4cBtDWuXGJ3pHbXtDb-QHeHAjNC5kxt6svifUNYqiq6GFxlW4RiwJuU_dW2zfWIj9XHIeamVSJg9G7j0DpbDnFV4tknLnPPK0_X_Dmn-mTP4WN_XH0eHt_93IHbgVgGj8dtacu3DFdffgxtya8vw-fD3-vJBx2y3b2id1xQPFhlZujHWHww0qkrPxtD7rh_iMkvp-qZiLp6We4lU_USYSYVkccHFLlSih3uv8ARwffvjy_mMSejEkBjHdlOiMWYO3H8YLY4TNuW1YgViK28ppwU3Fa16kjchs6hyVndi85qIyhc5M6qRgD2Gv6zv3GGJfy9rYukybmiPAkNalqWsqYxjedriIINtIRJlAVE79Mr4pHzBnUs1SVChF5aWoyghebX-zmmk6Lp39jgS9nUkU236gH05VsFjlBD0cZHhaI0bTpdbo_gxxB-S4O-1YBPsb-apg96O6EG4EL7af0WIpDKM716_9HAp_I0yI4NGsVduVsIKVxNEXgdjRt52l7n7p2qVnBZeVyNABR_B6o5kXy_r3X_Hk8l08hZs5GYsvwtyHvWlYu2dw3fyY2nF47q3tJ9j5MM4 priority: 102 providerName: ProQuest
Title	USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy
URI	https://link.springer.com/article/10.1038/s41467-022-29401-6 https://www.ncbi.nlm.nih.gov/pubmed/35361799 https://www.proquest.com/docview/2645765813 https://www.proquest.com/docview/2646727067 https://pubmed.ncbi.nlm.nih.gov/PMC8971425 https://doaj.org/article/e769071990584a6aa031c02542686ae3
Volume	13
WOSCitedRecordID	wos000777008300020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: P5Z dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M7P dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: PIMPY dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED_BAIkXNL5G2KiMxBtES2I7dh7ZtAkkqCJgUuEBy7EdNRJLqzZF2n_P2Um7ls8XXvJgO9Lp7nwfurufAV6g5TOSaxFnVe1iZqiIKy6rmNo857SuMeIIIK7vxHgsJ5Oi3Hrqy_eE9fDAPeOOnfD5W4pGE12lzrVGLTR-hDvLZa5dwPlMRLGVTAUbTAtMXdgwJZNQebxkwSb45vWswKQiznc8UQDs_12U-Wuz5E8V0-CIzvfh3hBBktc95ffhhmsfwJ3-Tcmrh_D14mMpSdNOmyp0Y5GFL-rM3ZLoFpdr1ABnSbe6nC3Ipe_G2xp1I91Ud2Q-63wLkQ9CccGRxo-QDINaV4_g4vzs0-mbeHhEITYYjHWxTqk1mLZQxo0RNmO2phyDIGYLpwUzBasYT2qR2sQ5Py9is4qJwnCNbHZS0Mew185a9wRIGEKtbZUndcUwMpDWJYmrC2MopilMRJCuGarMgDDuH7r4pkKlm0rVC0GhEFQQgsojeLn5Z97ja_z19ImX0-akx8YOC6gxatAY9S-NieBoLWU1XNilwrgQMy8uU9x-vtnGq-brJ7p1s1U44-vW6N8jOOiVYkMJ5TT34HoRiB112SF1d6dtpgHOWxYiRcsZwau1Yl2T9WdWPP0frDiEu5m_EWHG8gj2usXKPYPb5nvXLBcjuCkmInzlCG6dnI3LD6NwzUa-Q7bEb8m_4E759n35-Qf1UCfz
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHQheuF8CA4IETxAtiZ3YeUCI27RqXVWJTdpeMI7t0EosKW0K6p_iN3LsJB3lsrc98Oo4ke185_izzw3gKWo-xRPJgjgvTEAVYUGe8DwgOk0TUhTIOFwS1wEbDvnRUTbagB9dLIx1q-x0olPUulL2jnwbN26kxgmPyKvp18BWjbLW1a6ERgOLPbP8jke2-cv-O_y_z-J45_3B292grSoQKGQndSAjohXyeEITpZiOqS5IgqyA6sxIRlVGc5qEBYt0aIwNoNBxTlmmEhmp0HBG8LsXYJNasPdgc9TfHx2vbnVsvnVOaRudExK-PadOF1mn-TjDw0yQru2ArlDA39jtn06av1lq3Qa4c-1_W7rrcLWl2v7rRjZuwIYpb8Klpvjm8hZ8PPww4v6kHE9y57bmz6z1a2rmviyxuUBRMdqvFyfVzD-xbou_xAT69VjW_rSqra-VZevYYPyJjbVpI9qWt-HwXCZ3B3plVZp74Lto3ULnaVjkFCkU1yYMTZEpRfA8R5kHUYcAodpU7LYiyBfhXAIIFw1qBKJGONSI1IPnq3emTSKSM3u_scBa9bRJxF1DNfssWp0kDLNXIxHyEWShMpUSFbyy2RFinJ00xIOtDk-i1WxzcQomD56sHqNOsoYmWZpq4fpYAz8SIQ_uNihejYQkJLVZCD1ga_heG-r6k3IydnnPecYilDoPXnSScDqsfy_F_bNn8Rgu7x7sD8SgP9x7AFdiK6gu5HQLevVsYR7CRfWtnsxnj1pZ9-HTecvIT4Etjl8
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qZREX9iVQwEhwgmiS2ImdA0JAqahajUaCShWHGsd2mJFoMsxkQPPX-HU8O8mUYemtB66OE9nO954_-20AT1DzaZEqHiZFaUOmKQ-LVBQhNVmW0rJExuGTuO7z4VAcHuajDfjRx8I4t8peJ3pFbWrt7sgHuHEjNU5FTAdl5xYx2t55Of0augpSztLal9NoIbJnl9_x-DZ_sbuN__ppkuy8_fDmXdhVGAg1MpUmVDE1Gjk9ZanW3CTMlDRFhsBMbhVnOmcFS6OSxyay1gVTmKRgPNepinVkBaf43XNwnuMZ07kTjtKPq_sdl3ldMNbF6URUDObMayXnPp_keKwJs7W90JcM-BvP_dNd8zebrd8Kd67-z4t4Da50BJy8aiXmOmzY6gZcbEtyLm_C0cH7kSCTajwpvDMbmTmb2NTOiaqwuUQBsoY0i-N6Ro6dM-MvkYKkGauGTOvGeWA5Do8NlkxcBE4X57a8BQdnMrnbsFnVlb0LxMfwlqbIorJgSKyEsVFky1xriqc8xgOIezRI3SVod3VCvkjvKECFbBEkEUHSI0hmATxbvTNt05Oc2vu1A9mqp0st7hvq2WfZaSppubswiZGlIDdVmVKo9rXLmZDg7JSlAWz12JKdvpvLE2AF8Hj1GDWVMz-pytYL38eZ_ZEeBXCnRfRqJDSlmctNGABfw_raUNefVJOxz4Yuch7jxhPA814qTob176W4d_osHsElFAy5vzvcuw-XEyezPg51Czab2cI-gAv6WzOZzx56oSfw6awF5Ccm7ZXC
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=USP8+inhibition+reshapes+an+inflamed+tumor+microenvironment+that+potentiates+the+immunotherapy&rft.jtitle=Nature+communications&rft.au=Xiong%2C+Wenjun&rft.au=Gao%2C+Xueliang&rft.au=Zhang%2C+Tiantian&rft.au=Jiang%2C+Baishan&rft.date=2022-03-31&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=13&rft_id=info:doi/10.1038%2Fs41467-022-29401-6&rft_id=info%3Apmid%2F35361799&rft.externalDocID=PMC8971425
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon